Shares of Prana Biotechnology Ltd. (NASDAQ:PRAN) were up 30.7% during trading on Monday . The stock traded as high as $6.40 and last traded at $5.83, with a volume of 1,853,362 shares changing hands. The stock had previously closed at $4.46.

Separately, Zacks Investment Research upgraded shares of Prana Biotechnology from a “sell” rating to a “hold” rating in a research report on Wednesday, August 3rd.

The firm’s market cap is $8.46 million. The company’s 50 day moving average is $4.70 and its 200-day moving average is $3.82.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.